Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Daxibotulinumtoxin A
Therapeutic Area : Dermatology
Study Phase : Approved
Recipient : Revance Therapeutics
Deal Size : $924.0 million
Deal Type : Acquisition
Crown Laboratories and Revance Announce Entry into Merger Agreement
Details : Combined company's flagship brands will include DAXXIFY (daxibotulinumtoxinA-lanm), an acetylcholine release inhibitor and neuromuscular blocking agent.
Brand Name : Daxxify
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 12, 2024
Lead Product(s) : Daxibotulinumtoxin A
Therapeutic Area : Dermatology
Highest Development Status : Approved
Recipient : Revance Therapeutics
Deal Size : $924.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
